GlassScriptPhysician profile
Daniel Carter Lee
NPI 1811566532
$3,807.14
in general payments reported to CMS, 2019-2025
27 companies · $1,995 in 2025
The $1,995 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $41.62 · 2023: $583 · 2024: $1,188 · 2025: $1,995.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,766.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,765.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $417.43 | 2023-2025 | Briviact, Zilbrysq, Nayzilam |
| Sk Life Science, INC. | $415.81 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $373.79 | 2023-2025 | Ultomiris, Soliris |
| Abbvie INC. | $317.88 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $256.63 | 2023-2025 | Nuplazid, Daybue |
| Merz Pharmaceuticals, LLC | $245.35 | 2023-2025 | Xeomin, Ampyra, Inbrija |
| Novartis Pharmaceuticals Corporation | $224.70 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $219.46 | 2023-2025 | Epidiolex |
| Teva Pharmaceuticals USA, INC. | $194.87 | 2024-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Amgen INC. | $163.52 | 2025 | Uplizna |
| Neurocrine Biosciences, INC. | $162.83 | 2024-2025 | Ingrezza |
| Emd Serono, INC. | $98.63 | 2025 | Mavenclad |
| Genentech USA, INC. | $96.05 | 2024-2025 | Ocrevus, Ocrevus Zunovo |
| Takeda Pharmaceuticals U.S.A., INC. | $94.23 | 2023-2025 | Hyqvia |
| Biogen, INC. | $72.58 | 2023-2025 | Skyclarys, Vumerity, Tysabri |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $63.63 | 2023-2024 | Vyvgart, Vyvgart Hytrulo |
| Tanabe Pharma America, INC. | $61.63 | 2022-2023 | |
| Azurity Pharmaceuticals, INC. | $48.64 | 2024 | Zonisade |
| Upsher-Smith Laboratories LLC | $46.87 | 2025 | |
| Grifols USA, LLC | $44.74 | 2024 | Gamunex-C |
| Lundbeck LLC | $41.92 | 2025 | Vyepti |
| Janssen Biotech, INC. | $40.18 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $28.86 | 2024 | Rexulti |
| Vanda Pharmaceuticals INC. | $21.76 | 2024 | Ponvory |
| Astrazeneca Pharmaceuticals LP | $19.32 | 2025 | Wainua |
| Ptc Therapeutics, INC. | $19.23 | 2023 | |
| Catalyst Pharmaceuticals, INC. | $16.60 | 2023 | Fycompa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.